How to Save Money on Givlaari in 2026: Coupons, Discounts, and Patient Assistance

Givlaari (givosiran) is one of the most expensive medications in the United States. At a list price of approximately $39,000 per vial and a typical annual treatment cost of around $575,000, even small out-of-pocket costs can be financially devastating for patients and families. The good news: Alnylam Pharmaceuticals has significant patient support programs in place, and most commercially insured patients who qualify can dramatically reduce their costs.

This guide covers every financial assistance option available for Givlaari patients in 2026 — organized so you know exactly where to start based on your insurance situation.

Why Does Givlaari Cost So Much?

Givlaari is a novel RNA interference (RNAi) biologic for a rare disease affecting approximately 1 in 50,000 people. Rare disease drugs command premium prices in the U.S. market: the cost of development must be recouped across a very small patient population. Givlaari received Orphan Drug designation from the FDA, which grants extended market exclusivity to incentivize rare disease drug development. No generic is available, and the earliest estimated generic entry date is October 2034. These factors combine to make Givlaari's list price one of the highest in the country.

Option 1: Alnylam Assist® Commercial Copay Program

For commercially insured patients (those with private insurance or employer-sponsored coverage), the Alnylam Assist® Commercial Copay Program can significantly reduce or eliminate out-of-pocket costs for Givlaari. Key details:

• Eligible patients are those with commercial (private/employer) insurance — not Medicare, Medicaid, or other government-sponsored insurance
• Out-of-pocket costs for the administration of Givlaari are not covered under this program
• Patients where this program is prohibited by law are not eligible (check local regulations)

To enroll, contact Alnylam Assist® at 1-833-256-2748 or ask your prescriber to include you in the Givlaari Start Form enrollment.

Option 2: Alnylam Assist® Patient Assistance Program (PAP)

For patients who are primarily uninsured and meet specified financial criteria, Alnylam's Patient Assistance Program (PAP) provides Givlaari at no cost. This is Alnylam's commitment to ensuring that eligible patients who cannot afford coverage can still receive treatment.

Eligibility is determined based on income and financial need. Alnylam reserves the right to make eligibility determinations and may modify the program. Contact Alnylam Assist® at 1-833-256-2748 to learn if you qualify.

Option 3: Alnylam Assist® Bridge Program

If you are waiting for insurance coverage to be established or your prior authorization appeal is pending, the Alnylam Assist® Bridge Program can provide Givlaari at no cost during that gap. This is a critical resource for preventing treatment gaps while navigating the insurance system. Contact your Alnylam Assist® Case Manager immediately if your coverage has lapsed or is under appeal.

Option 4: Medicare and Medicaid Coverage

Medicare and Medicaid can cover Givlaari, but coverage varies by plan. Medicare Part D plans classify specialty drugs in the highest tier, meaning cost sharing can be substantial. The Inflation Reduction Act (IRA) implemented a $2,000 annual out-of-pocket cap on Medicare Part D spending starting in 2025, which can provide significant relief for patients who qualify.

Note: Medicare and Medicaid patients are NOT eligible for the Alnylam Assist® Commercial Copay Program. However, they may still be able to access the Patient Assistance Program if they meet financial criteria and are primarily uninsured. Medi-Cal expansion in California may also cover Givlaari for eligible low-income patients.

Option 5: Disease-Specific and Rare Disease Organizations

Several rare disease and porphyria patient advocacy organizations may be able to connect you with additional financial resources:

• American Porphyria Foundation (APF): Offers patient support, advocacy, and resource referrals at porphyriafoundation.org
• United Porphyrias Association: Maintains a resource hub with treatment access information
• NeedyMeds and RxAssist: National databases of patient assistance programs that may list additional resources
• State pharmaceutical assistance programs: Some states have programs that may offer supplemental assistance for specialty drug costs

Are There GoodRx Coupons or Discount Cards for Givlaari?

Givlaari is a specialty medication dispensed through a limited distribution network (CVS Specialty and Accredo only). Traditional retail pharmacy discount programs like GoodRx are generally not applicable to specialty biologics distributed this way — the medication cannot be dispensed through retail pharmacies where GoodRx pricing applies. The Alnylam Assist® programs are the primary financial assistance pathways for Givlaari.

What to Do Right Now

1. Call Alnylam Assist® at 1-833-256-2748 — they will assess your eligibility for every available program.
2. Have your insurance cards ready so they can check coverage and copay assistance eligibility quickly.
3. If you are denied coverage, ask about the Bridge Program immediately — don't let a coverage gap become a missed dose.
4. Use medfinder to locate the specialty pharmacy or clinical site that can administer your Givlaari so you are ready to receive your dose as soon as it is approved.

For more context on why Givlaari is expensive and hard to access, read our guide on why Givlaari is so hard to find.